导管原位癌术后全身治疗的影响
The impact of systemic therapy following ductal carcinoma in situ.
作者信息
Eng-Wong Jennifer, Costantino Joseph P, Swain Sandra M
机构信息
Department of Internal Medicine, Division of Oncology, Lombardi Cancer Center, Georgetown University, Washington, DC, USA.
出版信息
J Natl Cancer Inst Monogr. 2010;2010(41):200-3. doi: 10.1093/jncimonographs/lgq021.
Abstract
Following local therapy for ductal carcinoma in situ (DCIS), tamoxifen reduces the risk of ipsilateral and contralateral breast cancer by 30%-50%. Studies of tamoxifen in women with resected DCIS have not shown any effect on overall or cancer-specific survival. The adverse event profile of tamoxifen is well characterized, and individual risks and benefits should be assessed to guide decision making. We review the results of the phase III trials of tamoxifen in DCIS as well as the emerging risk reduction therapies.
摘要
对于导管原位癌（DCIS）进行局部治疗后，他莫昔芬可将同侧和对侧乳腺癌的风险降低30%-50%。对接受DCIS切除术的女性使用他莫昔芬的研究未显示对总生存率或癌症特异性生存率有任何影响。他莫昔芬的不良事件特征已得到充分描述，应评估个体的风险和益处以指导决策。我们回顾了他莫昔芬治疗DCIS的III期试验结果以及新出现的风险降低疗法。
相似文献
1
The impact of systemic therapy following ductal carcinoma in situ.
J Natl Cancer Inst Monogr. 2010;2010(41):200-3. doi: 10.1093/jncimonographs/lgq021.
2
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.
J Natl Cancer Inst Monogr. 2010;2010(41):162-77. doi: 10.1093/jncimonographs/lgq039.
3
The nature of tamoxifen action in the control of female breast cancer.
In Vivo. 2001 Jul-Aug;15(4):319-25.
4
The impact of adding radiation treatment after breast conservation surgery for ductal carcinoma in situ of the breast.
J Natl Cancer Inst Monogr. 2010;2010(41):187-92. doi: 10.1093/jncimonographs/lgq020.
5
The impact of surgery, radiation, and systemic treatment on outcomes in patients with ductal carcinoma in situ.
J Natl Cancer Inst Monogr. 2010;2010(41):130-3. doi: 10.1093/jncimonographs/lgq022.
6
Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
J Clin Oncol. 2012 Apr 20;30(12):1268-73. doi: 10.1200/JCO.2010.34.0141. Epub 2012 Mar 5.
7
Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.
J Natl Cancer Inst. 2011 Mar 16;103(6):478-88. doi: 10.1093/jnci/djr027. Epub 2011 Mar 11.
8
Radiotherapy and tamoxifen after breast-conserving surgery for DCIS.
Int J Fertil Womens Med. 2004 Sep-Oct;49(5):237-8.
9
Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS.
Int J Cancer. 2016 Nov 1;139(9):2127-34. doi: 10.1002/ijc.30254. Epub 2016 Jul 19.
10
Ductal carcinoma in situ, complexities and challenges.
J Natl Cancer Inst. 2004 Jun 16;96(12):906-20. doi: 10.1093/jnci/djh164.
引用本文的文献
1
Molecular subtypes predict second breast events of ductal carcinoma in situ after breast-conserving surgery.
Cancer Med. 2022 Jul;11(14):2755-2766. doi: 10.1002/cam4.4651. Epub 2022 May 22.
2
Efficacy of Emu Oil Transfersomes for Local Transdermal Delivery of 4-OH Tamoxifen in the Treatment of Breast Cancer.
Pharmaceutics. 2020 Aug 25;12(9):807. doi: 10.3390/pharmaceutics12090807.
3
Tamoxifen Initiation After Ductal Carcinoma In Situ.
Oncologist. 2016 Feb;21(2):134-40. doi: 10.1634/theoncologist.2015-0310. Epub 2016 Jan 14.
4
Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status.
Breast Cancer Res Treat. 2013 Jun;139(3):639-47. doi: 10.1007/s10549-013-2598-7. Epub 2013 Jun 18.
5
Effect of infertility treatment and pregnancy-related hormones on breast cell proliferation in vitro.
Hum Reprod. 2012 Jan;27(1):146-52. doi: 10.1093/humrep/der378. Epub 2011 Nov 10.
6
Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review.
J Cancer. 2011 May 1;2:232-61. doi: 10.7150/jca.2.232.
本文引用的文献
1
Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.
J Clin Oncol. 2009 Aug 10;27(23):3749-56. doi: 10.1200/JCO.2008.19.3797. Epub 2009 Jul 13.
2
The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial.
Curr Oncol. 2007 Jun;14(3):89-96. doi: 10.3747/co.2007.117.
3
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62. doi: 10.1093/jnci/dji372.
4
Aromatase inhibitors for breast cancer prevention.
J Clin Oncol. 2005 Mar 10;23(8):1636-43. doi: 10.1200/JCO.2005.11.027.
5
Neoadjuvant hormonal therapy for ductal carcinoma in situ: trial design and preliminary results.
Ann Surg Oncol. 2004 Jan;11(1 Suppl):37S-43S. doi: 10.1007/BF02524794.
6
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
N Engl J Med. 2004 Mar 11;350(11):1081-92. doi: 10.1056/NEJMoa040331.
7
Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ.
Cancer. 2004 Mar 1;100(5):942-9. doi: 10.1002/cncr.20085.
8
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
N Engl J Med. 2003 Nov 6;349(19):1793-802. doi: 10.1056/NEJMoa032312. Epub 2003 Oct 9.
9
Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial.
Lancet. 2003 Jul 12;362(9378):95-102. doi: 10.1016/s0140-6736(03)13859-7.
10
National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.
Clin Cancer Res. 2003 Jan;9(1 Pt 2):495S-501S.
Zotero 插件